And just to clarify before people start posting
"Rocket Emojis with to the moon tags"
this business wouldn't hit 3lk cr market cap in next 3 yrs but it can steadily compound at 25-30% YoY for next 10 yrs
At 25% CAGR over 10 yrs, you get a 10 bagger
Keep expectations in check.
Lets talk results #lauruslabs
— Tar \u26a1 (@itsTarH) July 29, 2021
Always zoom out and view the results, never take a QoQ approach.
Here is how Sales, Op.Profit and PAT looks like when you zoom out.
The upwards trends continues.
No business will move linearly up or linearly down. pic.twitter.com/O9UUt1rEE5
More from Tar ⚡
Market always moves to the cheaper alternative, slowly at first, then all of a sudden.
As more and more companies look towards the ESG factors, IEX would be a potential beneficiary.
— Kharanshu Parikh (@Kharanshu) August 7, 2021
Source: Suven Pharma\u2019s Annual Report
\u2066@itsTarH\u2069 pic.twitter.com/sRdMIAMaVP
More from Lauruslabs
Never Knowingly Misguide.
Money making and fake advisory/PMS propaganda has never been my agenda
In just 15 years, #LaurusLabs has scaled up like no other..!
— Conviction | Patience (@unseenvalue) July 5, 2020
Numbers v Narrative: Well balanced 2800 Cr sales + huge competitive advantage in terms of IP/patents/synthesis capability!
Comparing Laurus with others - 1 hrs 28 mins\U0001f447https://t.co/Zzx6AwHZLH
Conviction | Patience pic.twitter.com/I6bImfjDCW
Into a narrow consolidation band post breakout.
Sustained above the zone, Target's intact.
#StockMarket #StocksInFocus https://t.co/lhfemwd4iQ

#LAURUSLABS Multiple TF Analysis
— Gurleen (@GurleenKaur_19) August 9, 2021
A break-through at ATH.
Sustenance above 698 and a breakout at 705.85 would bring in higher targets of 733 followed by 800 in short term. #StockMarket #StocksToWatch pic.twitter.com/2aaY3BG99D